|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2004-7-1
|
|
pubmed:abstractText |
Therapeutics used to treat inflammatory diseases, including psoriatic arthritis (PsA), may potentially interfere with normal immune system function. Immune system function can be assessed by evaluating response to vaccination. We assessed the ability of patients with PsA treated with etanercept to produce antibodies in response to pneumococcal antigen challenge.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0315-162X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
31
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1356-61
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15229957-Adolescent,
pubmed-meshheading:15229957-Adult,
pubmed-meshheading:15229957-Aged,
pubmed-meshheading:15229957-Antirheumatic Agents,
pubmed-meshheading:15229957-Arthritis, Psoriatic,
pubmed-meshheading:15229957-Female,
pubmed-meshheading:15229957-Humans,
pubmed-meshheading:15229957-Immunocompetence,
pubmed-meshheading:15229957-Immunoglobulin G,
pubmed-meshheading:15229957-Male,
pubmed-meshheading:15229957-Middle Aged,
pubmed-meshheading:15229957-Pneumococcal Vaccines,
pubmed-meshheading:15229957-Receptors, Tumor Necrosis Factor
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept.
|
|
pubmed:affiliation |
Seattle Rheumatology Associates, 1101 Madison,. Suite 230, Seattle, WA 98104, USA. pmease@nwlink.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
